An observational study in Colo-rectal Cancer, sponsored by University Hospital, Brest. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by University Hospital, Brest · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Colonic Neoplasms with a site in France — 49 open to participants now, 66 under way, 13 of them phase 3. Colonic Neoplasms · France.
Among the 213 studies in Colonic Neoplasms with a site in France, this one is the 29th largest by planned enrollment of the 55 observational ones that give a count, is one of 9 that started in 2025, is one of 55 observational ones, reaches primary completion later than 27 of the 65 other live ones, and was the 198th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →49 of the 213 studies in Colonic Neoplasms with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Incyte Corporation · Sites in France, United States, Argentina and 19 more countries
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Spain
Ages 18+
Pfizer · Sites in France, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 56 · Phase 3 44 · Phase 4 3
First in 1990; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 227 across 555 observational studies indexed under Colonic Neoplasms.
Median enrollment 186 across the 143 interventional studies, 220 across the 55 observational. Of the 106 that completed or were terminated, 20 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 213 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
University Hospital, Brest has 3 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Colonic Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07000474University Hospital, BrestMultiparametric Characterization of Colorectal Cancers (METRAD) | 2026-12-31 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05577143University Hospital, LilleBlood Screening for Adult Colorectal Cancer | 2027-03 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT06287814University Hospital, MontpellierFrench Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) | 2027-04-11 |
Add all 10 to your calendar (.ics) → With an account.
Among the 213 studies in Colonic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary goal of this observational study is to assess the predictive value of a model developed through a multiparametric analysis of clinical images, histopathological data, CT scans, and molecular analysis. This analysis will be conducted on a retrospective cohort recruited at CHU Brest (training group). The model will then be validated using external cohorts from other centers (test group).
Around 20% of patients with colorectal cancer present with synchronous liver metastases at the time of diagnosis. In recent years, there has been increasing interest in the high-throughput extraction of quantitative data from medical images, a technique known as radiomics. Radiomic analysis can involve both qualitative and quantitative imaging parameters, which may be used independently or integrated into multiparametric prediction models.
This is a multicenter, retrospective study designed to investigate the demographic, clinical, and radiological features, treatment regimens, and outcomes of patients diagnosed with colorectal cancer. The study will involve the collection of anonymized clinical data, including age, sex, diagnosis date, treatment details, results from histopathological and genetic analyses, as well as pre- and post-treatment medical imaging typically performed as part of the management of colorectal cancer patients, along with survival and tumor recurrence data.
PRIMARY EVALUATION CRITERIA Prediction of recurrence/treatment response based on the radiomic model.
SECONDARY EVALUATION CRITERIA The impact of CT scan image acquisition and reconstruction parameters on the prognostic model.
The study population consists of patients diagnosed with colorectal cancer (CRC) who are undergoing various stages of treatment and care. The cohort includes individuals who have been surgically treated for colorectal cancer, with or without additional therapies such as chemotherapy, radiotherapy, or immunotherapy. The population may also include patients who have undergone routine follow-up care after treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have undergone surgery for colorectal cancer.
Exclusion Criteria:
Training cohort
Other: Omics
Validation cohort
Other: Omics
Multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
survival predictive model
The primary objective is to evaluate the predictive value of a model built through multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
Time frame: 2 years
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
Time frame: Data will be available beginning three years and ending fifteen years following the final study report completion
Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.